These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 35049446)

  • 1. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis.
    Siskind D; Orr S; Sinha S; Yu O; Brijball B; Warren N; MacCabe JH; Smart SE; Kisely S
    Br J Psychiatry; 2022 Mar; 220(3):115-120. PubMed ID: 35049446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders.
    Chan SKW; Chan HYV; Honer WG; Bastiampillai T; Suen YN; Yeung WS; Lam M; Lee WK; Ng RMK; Hui CLM; Chang WC; Lee EHM; Chen EYH
    Schizophr Bull; 2021 Mar; 47(2):485-494. PubMed ID: 33043960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CBTp for people with treatment refractory schizophrenia on clozapine: a systematic review and meta-analysis.
    Todorovic A; Lal S; Dark F; De Monte V; Kisely S; Siskind D
    J Ment Health; 2023 Feb; 32(1):321-328. PubMed ID: 33076721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register.
    Wellesley Wesley E; Patel I; Kadra-Scalzo G; Pritchard M; Shetty H; Broadbent M; Segev A; Patel R; Downs J; MacCabe JH; Hayes RD; de Freitas DF
    Schizophr Res; 2021 Jun; 232():68-76. PubMed ID: 34022618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response to pharmacological treatments in treatment-resistant schizophrenia - A systematic review and meta-analysis.
    Seppälä A; Pylvänäinen J; Lehtiniemi H; Hirvonen N; Corripio I; Koponen H; Seppälä J; Ahmed A; Isohanni M; Miettunen J; Jääskeläinen E
    Schizophr Res; 2021 Oct; 236():123-134. PubMed ID: 34496316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort.
    Kanahara N; Yamanaka H; Suzuki T; Takase M; Iyo M
    BMC Psychiatry; 2018 Sep; 18(1):274. PubMed ID: 30176881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical predictors of response to clozapine in Tunisian patients with treatment resistant schizophrenia.
    Aissa A; Jouini R; Ouali U; Zgueb Y; Nacef F; El Hechmi Z
    Compr Psychiatry; 2022 Jan; 112():152280. PubMed ID: 34763293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis.
    Lally J; Tully J; Robertson D; Stubbs B; Gaughran F; MacCabe JH
    Schizophr Res; 2016 Mar; 171(1-3):215-24. PubMed ID: 26827129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia.
    Cheuk NKW; Tse W; Tsui HKH; Ma CF; Chun JSW; Chung AKK; Chan SKW
    Schizophr Res; 2024 Jun; 268():205-222. PubMed ID: 37788946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naturalistic study on the use of clozapine in the early phases of non-affective psychosis: A 10-year follow-up study in the PAFIP-10 cohort.
    Moreno-Sancho L; Juncal-Ruiz M; Vázquez-Bourgon J; Ortiz-Garcia de la Foz V; Mayoral-van Son J; Tordesillas-Gutierrez D; Setien-Suero E; Ayesa-Arriola R; Crespo-Facorro B
    J Psychiatr Res; 2022 Sep; 153():292-299. PubMed ID: 35878537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates.
    Diniz E; Fonseca L; Rocha D; Trevizol A; Cerqueira R; Ortiz B; Brunoni AR; Bressan R; Correll CU; Gadelha A
    Braz J Psychiatry; 2023; 45(5):448-458. PubMed ID: 37718484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records.
    de Freitas DF; Patel I; Kadra-Scalzo G; Pritchard M; Shetty H; Broadbent M; Patel R; Downs J; Segev A; Khondoker M; MacCabe JH; Bhui K; Hayes RD
    Soc Psychiatry Psychiatr Epidemiol; 2022 Jul; 57(7):1341-1355. PubMed ID: 35246709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis.
    Mizuno Y; McCutcheon RA; Brugger SP; Howes OD
    Neuropsychopharmacology; 2020 Mar; 45(4):622-631. PubMed ID: 31766049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach.
    Barone A; De Prisco M; Altavilla B; Avagliano C; Balletta R; Buonaguro EF; Ciccarelli M; D'Ambrosio L; Giordano S; Latte G; Matrone M; Milandri F; Francesco DN; Vellucci L; de Bartolomeis A
    J Psychiatr Res; 2022 Nov; 155():572-578. PubMed ID: 36206601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study.
    Yasui-Furukori N; Muraoka H; Hasegawa N; Ochi S; Numata S; Hori H; Hishimoto A; Onitsuka T; Ohi K; Hashimoto N; Nagasawa T; Takaesu Y; Inagaki T; Tagata H; Tsuboi T; Kubota C; Furihata R; Iga JI; Iida H; Miura K; Matsumoto J; Yamada H; Watanabe K; Inada K; Shimoda K; Hashimoto R
    Neuropsychopharmacol Rep; 2022 Mar; 42(1):3-9. PubMed ID: 34854260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis.
    Siskind DJ; Lee M; Ravindran A; Zhang Q; Ma E; Motamarri B; Kisely S
    Aust N Z J Psychiatry; 2018 Aug; 52(8):751-767. PubMed ID: 29732913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment.
    Faden J; Citrome L
    Expert Opin Pharmacother; 2019 Jan; 20(1):11-24. PubMed ID: 30407873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role?
    Spangaro M; Martini F; Bechi M; Buonocore M; Agostoni G; Cocchi F; Sapienza J; Bosia M; Cavallaro R
    J Psychiatr Res; 2021 Sep; 141():346-352. PubMed ID: 34304039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia.
    O'Connell KS; Koch E; Lenk HÇ; Akkouh IA; Hindley G; Jaholkowski P; Smith RL; Holen B; Shadrin AA; Frei O; Smeland OB; Steen NE; Dale AM; Molden E; Djurovic S; Andreassen OA
    Psychiatry Res; 2023 Jul; 325():115217. PubMed ID: 37146461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia.
    Iasevoli F; Razzino E; Altavilla B; Avagliano C; Barone A; Ciccarelli M; D'Ambrosio L; Matrone M; Milandri F; Notar Francesco D; Fornaro M; de Bartolomeis A
    Early Interv Psychiatry; 2022 Apr; 16(4):352-362. PubMed ID: 33998142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.